Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2.
Vaccines (Basel). 2021 Sep 20;9(9):1047. doi: 10.3390/vaccines9091047.
Vaccines (Basel). 2021.
PMID: 34579284
Free PMC article.